巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2022-01-12
2023-03-06
2023-06-30
2021-11-28
2021-11-23
2021-08-06
2021-09-26
2023-07-16
2023-01-06
2021-07-17
2021-09-04
2021-04-23
